Insulet Co. (NASDAQ:PODD) Shares Acquired by AlphaQuest LLC

AlphaQuest LLC lifted its position in shares of Insulet Co. (NASDAQ:PODD) by 12,800.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,290 shares of the medical instruments supplier’s stock after purchasing an additional 1,280 shares during the quarter. AlphaQuest LLC’s holdings in Insulet were worth $337,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. PNC Financial Services Group Inc. grew its stake in Insulet by 0.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 13,028 shares of the medical instruments supplier’s stock worth $3,401,000 after buying an additional 59 shares during the period. EFG Asset Management Americas Corp. boosted its position in Insulet by 35.3% during the 4th quarter. EFG Asset Management Americas Corp. now owns 8,082 shares of the medical instruments supplier’s stock worth $2,110,000 after purchasing an additional 2,107 shares during the period. E Fund Management Co. Ltd. increased its holdings in Insulet by 53.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 1,359 shares of the medical instruments supplier’s stock valued at $355,000 after purchasing an additional 471 shares in the last quarter. Vestmark Advisory Solutions Inc. purchased a new position in Insulet in the fourth quarter valued at about $278,000. Finally, Inceptionr LLC acquired a new position in shares of Insulet during the fourth quarter worth about $1,327,000.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.47% of the company’s stock.

Analyst Ratings Changes

PODD has been the subject of a number of recent research reports. Citigroup increased their target price on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Stifel Nicolaus increased their price objective on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a research report on Friday, February 21st. Piper Sandler boosted their target price on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Wells Fargo & Company raised their price target on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Finally, Raymond James reiterated an “outperform” rating and issued a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $292.06.

Insulet Stock Up 4.4 %

PODD stock opened at $255.44 on Friday. The firm has a market cap of $17.94 billion, a price-to-earnings ratio of 44.12, a PEG ratio of 3.62 and a beta of 1.29. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The firm has a fifty day moving average price of $272.54 and a two-hundred day moving average price of $254.53. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.